|
1
|
Tie Y, Liu J, Wu Y, Qiang Y, Cai’Li G, Xu P, Xue M, Xu L, Li X, Zhou X. A Dataset for Constructing the Network Pharmacology of Overactive Bladder and Its Application to Reveal the Potential Therapeutic Targets of Rhynchophylline. Pharmaceuticals (Basel) 2024; 17:1253. [PMID: 39458894 PMCID: PMC11510256 DOI: 10.3390/ph17101253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2024] [Revised: 09/06/2024] [Accepted: 09/17/2024] [Indexed: 10/12/2024] Open
Abstract
Objectives: Network pharmacology is essential for understanding the multi-target and multi-pathway therapeutic mechanisms of traditional Chinese medicine. This study aims to evaluate the influence of database quality on target identification and to explore the therapeutic potential of rhynchophylline (Rhy) in treating overactive bladder (OAB). Methods: An OAB dataset was constructed through extensive literature screening. Using this dataset, we applied network pharmacology to predict potential targets for Rhy, which is known for its therapeutic effects but lacks a well-defined target profile. Predicted targets were validated through in vitro experiments, including DARTS and CETSA. Results: Our analysis identified Rhy as a potential modulator of the M3 receptor and TRPM8 channel in the treatment of OAB. Validation experiments confirmed the interaction between Rhy and these targets. Additionally, the GeneCards database predicted other targets that are not directly linked to OAB, corroborated by the literature. Conclusions: We established a more accurate and comprehensive dataset of OAB targets, enhancing the reliability of target identification for drug treatments. This study underscores the importance of database quality in network pharmacology and contributes to the potential therapeutic strategies for OAB.
Collapse
Affiliation(s)
- Yan Tie
- Department of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China; (Y.T.); (J.L.); (Y.W.); (Y.Q.); (G.C.); (P.X.); (M.X.)
- School of Chinese Medicine, Capital Medical University, Beijing 100069, China;
| | - Jihan Liu
- Department of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China; (Y.T.); (J.L.); (Y.W.); (Y.Q.); (G.C.); (P.X.); (M.X.)
- Department of Pharmacology, School of Basic Medical Sciences, Peking University, Beijing 100191, China
| | - Yushan Wu
- Department of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China; (Y.T.); (J.L.); (Y.W.); (Y.Q.); (G.C.); (P.X.); (M.X.)
| | - Yining Qiang
- Department of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China; (Y.T.); (J.L.); (Y.W.); (Y.Q.); (G.C.); (P.X.); (M.X.)
| | - Ge’Er Cai’Li
- Department of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China; (Y.T.); (J.L.); (Y.W.); (Y.Q.); (G.C.); (P.X.); (M.X.)
| | - Pingxiang Xu
- Department of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China; (Y.T.); (J.L.); (Y.W.); (Y.Q.); (G.C.); (P.X.); (M.X.)
| | - Ming Xue
- Department of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China; (Y.T.); (J.L.); (Y.W.); (Y.Q.); (G.C.); (P.X.); (M.X.)
| | - Liping Xu
- School of Chinese Medicine, Capital Medical University, Beijing 100069, China;
| | - Xiaorong Li
- Department of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China; (Y.T.); (J.L.); (Y.W.); (Y.Q.); (G.C.); (P.X.); (M.X.)
| | - Xuelin Zhou
- Department of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China; (Y.T.); (J.L.); (Y.W.); (Y.Q.); (G.C.); (P.X.); (M.X.)
| |
Collapse
|